Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
Sources (9)
- Kailera weight loss pill trial results: nausea sinks stock qz.com · 36d ago
- Kailera Therapeutics Announces Positive Topline Data from GlobeNewswire · 36d ago
- Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending BioSpace · 36d ago
- Kailera's GLP-1 drug meets main goal of late-stage trials Yahoo Finance · 36d ago
- Kailera says obesity pill succeeds in late-stage trial in China BioPharma Dive · 36d ago
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials Endpoints News · 36d ago
- Kailera shares tumble on high nausea rates despite weight-loss drug's success Reuters · 36d ago
- Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials Fierce Biotech · 36d ago
- Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback Investor's Business Daily · 36d ago broke it first
The brief
Kailera's oral GLP-1 asset achieved its goals in Chinese phase 3 obesity and diabetes trials, demonstrating an 11% weight loss. However, the drug experienced high rates of nausea and other side effects.
Coverage from Reuters, Endpoints News, BioPharma Dive, and Fierce Biotech emphasizes that while the pill showed encouraging efficacy, the side effect profile caused Kailera's shares to tumble. Investor's Business Daily reports that this setback coincided with an increase in Eli Lilly's market capitalization.
Future developments depend on how Kailera addresses the high side effect rates reported in the late-stage trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 36d ago.
Quick answers
What were the results of Kailera's late-stage trials in China?
The oral GLP-1 asset hit its goals, with reports of 11% weight loss.
Why did Kailera's shares decline despite the drug's efficacy?
Shares tumbled due to high rates of nausea and other side effects observed during the trials.
How did this news affect Eli Lilly?
According to Investor's Business Daily, Eli Lilly's market cap increased following the setback.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
From around our network
Related trends
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
Typhoon Dolphin: China evacuates more than 1 million people as massive storm arrives
Typhoon Dolphin forces China to evacuate over a million as record rains batter Shanghai
Taipei says China's traffic control order for Taiwan Strait during typhoon is 'ridiculous'
Taipei has dismissed Beijing's Taiwan Strait traffic control order during a typhoon as ridiculous amidst rising regional tensions.
Typhoon Dolphin hits Japan's Okinawa, China shuts ports ahead of landfall
Typhoon Dolphin slams into Japan's Okinawa before tracking toward China.
China's exports growth beats estimates in July, as AI-driven shipments surge
China's exports jumped almost a quarter in July, driven by a surging tech cycle and strong demand for artificial intelligence shipments.
GLP-1 Drugs May Have a Hidden Effect on Your Eyes, Study Finds
New safety guidance and a lawsuit spotlight a possible eye‑risk link in popular GLP-1 weight‑loss drugs.